We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Loss-of-Function Mutation Causes ALS in Mouse Model

By LabMedica International staff writers
Posted on 25 Jul 2016
Neurological disease researchers working with a mouse model of amyotrophic lateral sclerosis (ALS) have shown that the condition is critically linked to a loss-of-function mutation in the C9ORF72 (chromosome 9 open reading frame 72) gene.

C9ORF72 mutations have been found in a significant fraction of patients suffering from ALS and frontotemporal dementia (FTD), yet the function of the C9ORF72 gene product remains poorly understood.

In a study published in the July 14, 2016, online edition of the journal Science Translational Medicine investigators at Harvard University (Cambridge, MA, USA) and the Massachusetts Institute of Technology (Cambridge, MA, USA) described results of experiments performed with an ALS mouse model.

They reported that mice carrying loss-of-function mutations in C9ORF72 developed splenomegaly, neutrophilia, thrombocytopenia, increased expression of inflammatory cytokines, and severe autoimmunity, ultimately leading to a high mortality rate. More...
Transplantation of mutant mouse bone marrow into wild-type recipients was sufficient to create the phenotypes observed in the mutant animals, including autoimmunity and premature mortality. Reciprocally, transplantation of wild-type mouse bone marrow into mutant mice improved their phenotype.

Knockout mice – genetically engineered to lack the C9ORF72 gene – that received a bone marrow transplant from normal animals lived on average 43 days longer, weighed more, and had a greater number of blood platelets throughout their lifespan than did untreated knockout mice.

"The point of our paper was to determine the function of this gene and what it normally helps to do in the body," said senior author Dr. Kevin Eggan, professor of stem cell and regenerative biology at Harvard University. "The mice seemed to get better, but the bone marrow transplant did not wholly rescue the animals, suggesting that there may also be functions of C9ORF72 in other organs."

Related Links:
Harvard University
Massachusetts Institute of Technology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Thyroid Test
Anti-Thyroid EIA Test
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.